Nano Software Services

iSERA Lifesciences Ltd.

ISERA

Market Cap
₹121 Cr.
P/E
465.40

iSERA Lifesciences Ltd.

  • iSERA Lifesciences
  • Xelpmoc Design &Tech
  • GVP Infotech

FAQs on iSERA Lifesciences Ltd. Shareprice

iSERA Lifesciences has given better returns compared to its competitors.
iSERA Lifesciences has grown at ~8394.47% over the last 2yrs while peers have grown at a median rate of -19.65%

Yes, iSERA Lifesciences is expensive.
Latest PE of iSERA Lifesciences is 465, while 3 year average PE is 56.46.
Also latest EV/EBITDA of iSERA Lifesciences is 449 while 3yr average is 29.76.

View FAQ's On Business

Growth Table

  • iSERA Lifesciences Ltd.
  • Xelpmoc Design &Tech
  • GVP Infotech

Balance Sheet

  • iSERA Lifesciences Ltd.
  • Xelpmoc Design &Tech
  • GVP Infotech

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • iSERA Lifesciences Ltd.
  • Xelpmoc Design &Tech
  • GVP Infotech

Cash Flow

  • iSERA Lifesciences Ltd.
  • Xelpmoc Design &Tech
  • GVP Infotech

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • iSERA Lifesciences Ltd.
  • Xelpmoc Design &Tech
  • GVP Infotech

Quarterly Results

  • iSERA Lifesciences Ltd.
  • Xelpmoc Design &Tech
  • GVP Infotech

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on iSERA Lifesciences Ltd. Financials

Balance sheet of iSERA Lifesciences is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of iSERA Lifesciences is increasing.
Latest net debt of iSERA Lifesciences is ₹1.56 Crs as of Mar-25.
This is greater than Mar-24 when it was ₹0.18 Crs.

Yes, profit is increasing.
The profit of iSERA Lifesciences is ₹0.14 Crs for Mar 2025, -₹0.1 Crs for Mar 2024 and -₹0.11 Crs for Mar 2023

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
iSERA Lifesciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Short Term Loans & Advances

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech